

# Jonathon R Campbell

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8301910/publications.pdf>

Version: 2024-02-01

52  
papers

2,042  
citations

394286

19  
h-index

265120

42  
g-index

54  
all docs

54  
docs citations

54  
times ranked

4150  
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis. <i>BMJ, The</i> , 2020, 370, m2516.	3.0	673
2	Proportion of asymptomatic infection among COVID-19 positive persons and their transmission potential: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2020, 15, e0241536.	1.1	250
3	The Sensitivity and Costs of Testing for SARS-CoV-2 Infection With Saliva Versus Nasopharyngeal Swabs. <i>Annals of Internal Medicine</i> , 2021, 174, 501-510.	2.0	160
4	Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. <i>Lancet Respiratory Medicine</i> , 2020, 8, 383-394.	5.2	155
5	Absolute risk of tuberculosis among untreated populations with a positive tuberculin skin test or interferon-gamma release assay result: systematic review and meta-analysis. <i>BMJ, The</i> , 2020, 368, m549.	3.0	58
6	Standardised shorter regimens versus individualised longer regimens for rifampin- or multidrug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2020, 55, 1901467.	3.1	55
7	A Systematic Review on TST and IGRA Tests Used for Diagnosis of LTBI in Immigrants. <i>Molecular Diagnosis and Therapy</i> , 2015, 19, 9-24.	1.6	50
8	Mortality in adults with multidrug-resistant tuberculosis and HIV by antiretroviral therapy and tuberculosis drug use: an individual patient data meta-analysis. <i>Lancet, The</i> , 2020, 396, 402-411.	6.3	49
9	Predicting tuberculosis relapse in patients treated with the standard 6-month regimen: an individual patient data meta-analysis. <i>Thorax</i> , 2019, 74, 291-297.	2.7	41
10	Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials. <i>Lancet Infectious Diseases, The</i> , 2020, 20, 318-329.	4.6	37
11	Latent Tuberculosis Infection Screening in Immigrants to Low-Incidence Countries: A Meta-Analysis. <i>Molecular Diagnosis and Therapy</i> , 2015, 19, 107-117.	1.6	30
12	Active testing of groups at increased risk of acquiring SARS-CoV-2 in Canada: costs and human resource needs. <i>Cmaj</i> , 2020, 192, E1146-E1155.	0.9	30
13	Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study. <i>Lancet Infectious Diseases, The</i> , 2022, 22, 1042-1051.	4.6	28
14	Treatment of latent infection to achieve tuberculosis elimination in low-incidence countries. <i>PLoS Medicine</i> , 2019, 16, e1002824.	3.9	27
15	Estimated Impact of World Health Organization Latent Tuberculosis Screening Guidelines in a Region With a Low Tuberculosis Incidence: Retrospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2019, 69, 2101-2108.	2.9	26
16	Effect of Intermittency on Treatment Outcomes in Pulmonary Tuberculosis: An Updated Systematic Review and Metaanalysis. <i>Clinical Infectious Diseases</i> , 2017, 64, 1211-1220.	2.9	25
17	Demographic predictors of active tuberculosis in people migrating to British Columbia, Canada: a retrospective cohort study. <i>Cmaj</i> , 2018, 190, E209-E216.	0.9	24
18	Testing the External Validity of a Discrete Choice Experiment Method: An Application to Latent Tuberculosis Infection Treatment. <i>Value in Health</i> , 2017, 20, 969-975.	0.1	22

#	ARTICLE	IF	CITATIONS
19	Evidence-based Definition for Extensively Drug-Resistant Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 713-722.	2.5	22
20	A Systematic Review of Studies Evaluating the Cost Utility of Screening High-Risk Populations for Latent Tuberculosis Infection. <i>Applied Health Economics and Health Policy</i> , 2015, 13, 325-340.	1.0	21
21	The latent tuberculosis cascade-of-care among people living with HIV: A systematic review and meta-analysis. <i>PLoS Medicine</i> , 2021, 18, e1003703.	3.9	21
22	Burden of non-adherence to latent tuberculosis infection drug therapy and the potential cost-effectiveness of adherence interventions in Canada: a simulation study. <i>BMJ Open</i> , 2017, 7, e015108.	0.8	20
23	Health System Costs of Treating Latent Tuberculosis Infection With Four Months of Rifampin Versus Nine Months of Isoniazid in Different Settings. <i>Annals of Internal Medicine</i> , 2020, 173, 169-178.	2.0	20
24	Cost-effectiveness of Latent Tuberculosis Infection Screening before Immigration to Low-Incidence Countries. <i>Emerging Infectious Diseases</i> , 2019, 25, 661-671.	2.0	19
25	Safety and Efficacy of Rifampin or Isoniazid Among People With Mycobacterium tuberculosis Infection and Living With Human Immunodeficiency Virus or Other Health Conditions: Post Hoc Analysis of 2 Randomized Trials. <i>Clinical Infectious Diseases</i> , 2020, 73, e3545-e3554.	2.9	19
26	Economic and modeling evidence for tuberculosis preventive therapy among people living with HIV: A systematic review and meta-analysis. <i>PLoS Medicine</i> , 2021, 18, e1003712.	3.9	19
27	Tuberculosis preventive therapy for people living with HIV: A systematic review and network meta-analysis. <i>PLoS Medicine</i> , 2021, 18, e1003738.	3.9	18
28	Adequacy of Serial Self-performed SARS-CoV-2 Rapid Antigen Detection Testing for Longitudinal Mass Screening in the Workplace. <i>JAMA Network Open</i> , 2022, 5, e2210559.	2.8	18
29	Predicting tuberculosis risk in the foreign-born population of British Columbia, Canada: study protocol for a retrospective population-based cohort study. <i>BMJ Open</i> , 2016, 6, e013488.	0.8	15
30	Cost-effectiveness of post-landing latent tuberculosis infection control strategies in new migrants to Canada. <i>PLoS ONE</i> , 2017, 12, e0186778.	1.1	15
31	Screening for Latent Tuberculosis Infection in Migrants With CKD: A Cost-effectiveness Analysis. <i>American Journal of Kidney Diseases</i> , 2019, 73, 39-50.	2.1	11
32	The mTST – An mHealth approach for training and quality assurance of tuberculin skin test administration and reading. <i>PLoS ONE</i> , 2019, 14, e0215240.	1.1	9
33	Prevalence, acceptability, and cost of routine screening for pulmonary tuberculosis among pregnant women in Cotonou, Benin. <i>PLoS ONE</i> , 2022, 17, e0264206.	1.1	9
34	Scaling up target regimens for tuberculosis preventive treatment in Brazil and South Africa: An analysis of costs and cost-effectiveness. <i>PLoS Medicine</i> , 2022, 19, e1004032.	3.9	6
35	Scaling up investigation and treatment of household contacts of tuberculosis patients in Brazil: a cost-effectiveness and budget impact analysis. <i>The Lancet Regional Health Americas</i> , 2022, 8, 100166.	1.5	5
36	Safety of prolonged treatment with bedaquiline in programmatic conditions. <i>ERJ Open Research</i> , 2022, 8, 00685-2021.	1.1	5

#	ARTICLE	IF	CITATIONS
37	Low Body Mass Index at Treatment Initiation and Rifampicin-Resistant Tuberculosis Treatment Outcomes: An Individual Participant Data Meta-Analysis. <i>Clinical Infectious Diseases</i> , 2022, 75, 2201-2210.	2.9	5
38	Changes in treatment for multidrug-resistant tuberculosis according to national income. <i>European Respiratory Journal</i> , 2020, 56, 2001394.	3.1	4
39	Tuberculosis preventive treatment in people living with HIV—Is the glass half empty or half full?. <i>PLoS Medicine</i> , 2021, 18, e1003702.	3.9	4
40	High-dose rifamycins in the treatment of TB: a systematic review and meta-analysis. <i>Thorax</i> , 2022, 77, 1210-1218.	2.7	4
41	How Well Does TSTin3D Predict Risk of Active Tuberculosis in the Canadian Immigrant Population? An External Validation Study. <i>Clinical Infectious Diseases</i> , 2021, 73, e3486-e3495.	2.9	3
42	Chapter 4: Diagnosis of tuberculosis infection. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2022, 6, 49-65.	0.2	3
43	No time to waste: preventing tuberculosis in children. <i>Lancet, The</i> , 2020, 395, 924-926.	6.3	2
44	Systematic on-site testing for SARS-CoV-2 infection among asymptomatic essential workers in Montréal, Canada: a prospective observational and cost-assessment study. <i>CMAJ Open</i> , 2022, 10, E409-E419.	1.1	2
45	The Role of Tuberculosis Screening Among Migrants to Low-Incidence Settings in (Not) Achieving Elimination. <i>American Journal of Epidemiology</i> , 2021, , .	1.6	1
46	What makes a score a winner?. <i>Lancet Infectious Diseases, The</i> , 2020, 20, 10-11.	4.6	0
47	Build back better: Advances in tuberculosis research in Canada & globally in 2020. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2021, 5, 121-124.	0.2	0
48	Title is missing!. , 2020, 15, e0241536.		0
49	Title is missing!. , 2020, 15, e0241536.		0
50	Title is missing!. , 2020, 15, e0241536.		0
51	Title is missing!. , 2020, 15, e0241536.		0
52	Occupational stress in industry setting in Benin 2019: A cross-sectional study. <i>PLoS ONE</i> , 2022, 17, e0269498.	1.1	0